title: Direct cardiac injection of G-CSF mobilized bone-marrow stem-cells improves ventricular function in old myocardial infarction.
abstract: Autologous transplant of bone marrow stem cells (BMSC), although extremely useful after acute myocardial events, has not been evaluated in patients with old (>one-year-old) myocardial infarction. Our aim was to determine if CD34(+)-enriched peripheral-blood cells, obtained by apheresis, injected directly into the severely damaged myocardium of five patients with old myocardial infarction could restore depressed myocardial function. We found that 28 weeks after revascularization and peri-infarction injection of the enriched CD34(+) peripheral mononuclear cells, ventricular hemodynamic parameters that included left ventricular ejection fraction, left ventricular diastolic volume, ventricular systolic volume and left ventricular diastolic diameter approximated normal values and there was no restenosis; two patients have been followed for >52 weeks and their parameters are within normal values. In conclusion, intramyocardial injection of easily obtained CD34(+) enriched peripheral blood cells represent an encouraging procedure for patients with severely scarred and dysfunctional myocardium.
authors.affiliation: Departamento de Cirugía Cardiovascular, CMN 20 de Noviembre, ISSSTE, México DF, México.
authors.forename: Abel
authors.initials: A
authors.lastname: Archundia
authors.forename: José Luis
authors.initials: JL
authors.lastname: Aceves
authors.forename: Manuel
authors.initials: M
authors.lastname: López-Hernández
authors.forename: Martha
authors.initials: M
authors.lastname: Alvarado
authors.forename: Emma
authors.initials: E
authors.lastname: Rodriguez
authors.forename: Guillermo
authors.initials: G
authors.lastname: Díaz Quiroz
authors.forename: Araceli
authors.initials: A
authors.lastname: Páez
authors.forename: Felipe Masso
authors.initials: FM
authors.lastname: Rojas
authors.forename: Luis Felipe
authors.initials: LF
authors.lastname: Montaño
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000378:metabolism; D001854:Bone Marrow Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006321:Heart / Q000000981:diagnostic imaging; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*; D009204:Myocardial Revascularization; D011877:Radionuclide Imaging; D011994:Recombinant Proteins; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D016277:Ventricular Function, Left
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim